tirzepatide kidneys (Zepbound) showed improved kidney function in obese patients with both chronic kidney disease and #heartfailure with preserved ejection fraction, highlighting its potential to address this high-risk patient population. Read more: https Tirzepatide Shows Kidney Benefits in

KPV tackles the inferno in the gut, a primary source of systemic inflammation

Wayman GA, Kaech S, Grant WF, Davare M, Impey S, Tokumitsu H, et al

days 1 to 30): 3 mg orally once a day Dose escalation (days 31 to 60): 7 mg orally once a day Maintenance dose (day 61 and onward): If no additional glycemic control is needed: 7 mg orally once a day If additional glycemic control is needed: 14 mg orally once a day SUBCUTANEOUS: Ozempic Injection: Initial dose: 0.25 mg subcutaneously once a week for 4 weeks, then 0.5 mg subcutaneously once a week Maintenance dose: 0.5 to 2 mg subcutaneously once a week, based on glycemic control If additional glycemic control is needed after at least 4 weeks on the 0.5 mg dose: Increase to 1 mg subcutaneously once a week

J.O'connorG

To date, the most effective injectable weight loss drugs are semaglutide and tirzepatide

Fahey, R